Center for Innovative Phage Applications and Therapeutics (IPATH)’s Post

Did you know there are over 7,000 known rare diseases in the world, affecting about 400 million people? These diseases represent a huge burden of unmet patient needs with very limited treatment options currently available. Many of these conditions remain undiagnosed and are referred to as SWAN (syndromes without a name). This has led to the creation of various initiatives including the outstanding European Joint Programme on Rare Diseases (EJP-RD), part of the ERN-RND, European Reference Network for Rare Neurological Diseases, which promote and drive treatment discovery but also patient care, support and education. Indeed, as well as leading dedicated research globally into these very distressing conditions, it is vital that patients and their loved ones have access to a broad range of support and information resources, available in their *own language*. #rarediseases #patientsupport #research #outreach #languagematters #xl8 https://lnkd.in/ekRNshGz

Inositol + IP6 (InoCell) in Diabetes: New Frontiers for the Use of IP6 and Inositol Combination in Treating Diabetes Mellitus: A Review - PubMed (nih.gov)

Our latest publication in the Journal of Clinical Case Reports and Images sheds light on a rare yet impactful phenomenon: Rapid Calcification of Myocardium as a Sequela from Severe Sepsis. 🫁 Our study delves into the dynamic development of myocardial calcification within just 10 weeks in a 60-year-old male patient battling severe sepsis. 📚 This peer-reviewed open access journal article uncovers the potential link between severe sepsis and myocardial calcification, offering crucial insights into its pathogenesis. Our patient, undergoing palliative therapy for multiple myeloma, experienced a pneumogenic sepsis, leading to unexpected calcifications in the left ventricle's outer myocardial layers. 🔍 Explore the full study to understand the implications of this discovery and its significance in clinical practice. Dive deep into the intricate details of our findings and contribute to the ongoing discussion on this intriguing topic. 💡 🔗 Read the full article here: https://lnkd.in/gjEaKkVe #Research #MedicalScience #MyocardialCalcification #Sepsis #ClinicalCaseReports #OpenAccessJournal

Learn more about the key features of complex immune issues with experienced naturopath Emma Sutherland during our upcoming Clinical Mastery Webinar: Demystifying Clinical Strategies for Complex Autoimmune Cases.   Over 5% of Australians suffer from autoimmune conditions, often with multiple, overlapping diagnoses. These conditions present significant challenges linked to environmental stressors that impact the microbiome and immune system.   Join clinical naturopath and fx Medicine ambassador Emma Sutherland in a 90-minute masterclass. Emma will share insights from her practice on simplifying the management of complex autoimmune cases to improve outcomes and patient compliance.   Highlights: - A case study approach to autoimmune gastritis and pernicious anaemia. - Strategies to streamline your clinical approach and tailor patient management. - Understanding key autoimmune drivers like mucosal immune disruption and microbiota dysbiosis. - Practical tips for precise patient assessment and evidence-based treatment strategies. - Reserve your spot now and gain actionable insights into managing complex autoimmune disorders effectively.   CPD points apply. The webinar is classified as 1.5 hours of learning. DATE: 22 May 2024   Get your ticket today! https://lnkd.in/eSTyg3hE #clinicalmastery #clinicaleducation 

Are diagnostic errors harming more than we know? Read this article shedding light on the hidden toll of misdiagnosis. At Canary Speech, we're leading the charge in improving diagnostic accuracy to save lives. https://lnkd.in/dJZU4-MH #HealthcareInnovation #DiagnosticExcellence #CanarySpeech Johns Hopkins Medicine

There are so many examples of how better understanding of the natural history of diseases helps improve people’s care. In the case of the presymptomatic stages of type 1 diabetes, identifying markers of disease progression will be pivotal for choosing the right monitoring cadence and management for each person. That’s why here at European Association for the Study of Diabetes e.V. (EASD), investigators are making our heads spin showing us they are on a fast track to find factors of prediction of disease progression. Just a few examples: - Teams at the Helmholtz Munich are improving polygenic risk scores and enhancing the precision of metabolic staging. - On the other side of the Atlantic, Prof. Emily Sims collected compelling evidence that positivity for IA-2A is associated with a high risk of progression independently from glycemic status. Like I said, the more people at high risk of fast progression can be identified, the better the care and the softer the transition to stage 3 T1D. Want to know more about Islet autoantibodies as precision diagnostic tools in aT1D? Felton JL et al, Commun Med (Lond). 2024 Apr 6;4(1):66. doi: 10.1038/s43856-024-00478-y. PMID: 38582818; PMCID: PMC10998887.Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review - PMC (nih.gov) #naturalhistory, #type1diabetes, #precisionmedicine, #earlydetection

Coming up: Webinar by #NovaBiomedical "Key Updates, Including ePV, for Managing Sepsis and Septic Shock" With Sepsis prognosis being improved through advances in critical care management, mortality from sepsis remains high. Dr. Devang Sanghavi, Vice Chair of Practice, Critical Care Medicine, Mayo Clinic, will review key considerations and controversies surrounding sepsis identification and resuscitation. He will review clinical studies of estimated plasma volume (ePV), an important new tool for managing the volume status of critically ill patients. 🗓️ March 26, 2024 ⏰ 11:00 AM GMT Register here 🔗 https://iii.hm/1ovt @Nova Biomedical #SepsisManagement #SepticShock #CriticalCare #ePV #CriticalCareManagement

Today is the annual Clinical Trials Day – a day to honour clinical research that is crucial for both individual patients and society as a whole. As we know, access to clinical trials may be the last straw for patients to overcome their disease, for example in cancers or neurological diseases, when no treatment is yet available or existing therapies are ineffective. 👨⚕️ The Medfiles Clinical Team is happy to be part of several ongoing and coming trials. We celebrate the sponsors, sites, study nurses, investigators, other CROs and above all – the patients – who make it all possible. Let’s keep up the good work and co-operation! #CTD2024 #clinicaltrials #clinicalresearch #clinicalinvestigation